Dispatch Bio Initiates Clinical Trials for a New Type of Cancer Treatment 

Dispatch Bio, co-founded by Carl June, MD, the Richard W. Vague Professor in Immunotherapy at Penn Medicine, is developing a cancer treatment platform that uses a virus to deliver an optimized universal antigen to tumor cells, effectively labeling them for subsequent targeting by CAR-T cells.  The technology is intended to overcome a key limitation of current CAR-T cell therapies by broadening the range of tumors that can be targeted and treated. Learn more here and here. The company was also recently featured in Nature Biotechnology. 

Skip to content